Target Information

Target General Infomation
Target ID
T34843
Former ID
TTDNS00544
Target Name
Glucagon-like peptide 2 receptor
Gene Name
GLP2R
Synonyms
GLP2 receptor; GLP2R
Target Type
Successful
Disease Diarrhea [ICD9: 787.91; ICD10: A09, K59.1]
Gastrointestinal disease [ICD10: K00-K93]
Inflammatory bowel disease [ICD9: 555, 556; ICD10: K50, K51]
Osteoporosis [ICD9: 733.0, V07.4; ICD10: M80-M81, Z79.890]
Short bowel syndrome [ICD9: 579.3; ICD10: K91.8]
Function
This is a receptor for glucagon-like peptide 2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
BioChemical Class
GPCR secretin
UniProt ID
O95838
Sequence
MKLGSSRAGPGRGSAGLLPGVHELPMGIPAPWGTSPLSFHRKCSLWAPGRPFLTLVLLVS
IKQVTGSLLEETTRKWAQYKQACLRDLLKEPSGIFCNGTFDQYVCWPHSSPGNVSVPCPS
YLPWWSEESSGRAYRHCLAQGTWQTIENATDIWQDDSECSENHSFKQNVDRYALLSTLQL
MYTVGYSFSLISLFLALTLLLFLRKLHCTRNYIHMNLFASFILRTLAVLVKDVVFYNSYS
KRPDNENGWMSYLSEMSTSCRSVQVLLHYFVGANYLWLLVEGLYLHTLLEPTVLPERRLW
PRYLLLGWAFPVLFVVPWGFARAHLENTGCWTTNGNKKIWWIIRGPMMLCVTVNFFIFLK
ILKLLISKLKAHQMCFRDYKYRLAKSTLVLIPLLGVHEILFSFITDDQVEGFAKLIRLFI
QLTLSSFHGFLVALQYGFANGEVKAELRKYWVRFLLARHSGCRACVLGKDFRFLGKCPKK
LSEGDGAEKLRKLQPSLNSGRLLHLAMRGLGELGAQPQQDHARWPRGSSLSECSEGDVTM
ANTMEEILEESEI
Drugs and Mode of Action
Drug(s) Teduglutide Drug Info Approved Short bowel syndrome [524696], [542060], [551871]
Elsiglutide Drug Info Phase 2 Diarrhea [523812]
SAN-134 Drug Info Phase 1 Osteoporosis [547975]
ZP-1848 Drug Info Phase 1 Inflammatory bowel disease [522615]
Modulator AMX-256 Drug Info [543640]
Elsiglutide Drug Info [550039]
FE-203799 Drug Info [543640]
Teduglutide Drug Info [551871]
ZP-1848 Drug Info [550930]
Inhibitor SAN-134 Drug Info [547976]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Neuroactive ligand-receptor interaction
Reactome G alpha (s) signalling events
Glucagon-type ligand receptors
WikiPathways GPCRs, Class B Secretin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 522615ClinicalTrials.gov (NCT00868660) Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose.
Ref 523812ClinicalTrials.gov (NCT01543451) Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea. U.S. National Institutes of Health.
Ref 524696ClinicalTrials.gov (NCT02099084) Short Bowel Syndrome and Teduglutide VS Placebo. U.S. National Institutes of Health.
Ref 542060(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7049).
Ref 547975Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020865)
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 543640(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 250).
Ref 547976Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020865)
Ref 550039Poster Abstracts. Volume 10, Issue Supplement S8, pages 126-209, December 2014.
Ref 550930US patent application no. 8,580,918, Peptidic glp-2 agonists.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.